Heterologous prime boost vaccination with DNA and recombinant modified vaccinia virus Ankara protects IFNAR(-/-) mice against lethal bluetongue infection

Vaccine

Volumn 28, Issue 2, 2009, Pages 437-445

  Calvo Pinilla, Eva ^a   Rodríguez Calvo, Teresa ^a   Sevilla, Noemí ^a   Ortego, Javier ^a  

^a Instituto Nacional de Investigación y Tecnología Agraria y Alimentaria   (Spain)

Author keywords

BTV; DNA rMVA vaccination; Prime boost

Indexed keywords

ALPHA BETA INTERFERON RECEPTOR; DNA VACCINE; GAMMA INTERFERON; NEUTRALIZING ANTIBODY; NONSTRUCTURAL PROTEIN 3; PROTEIN VP2; PROTEIN VP5; PROTEIN VP7; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG; VACCINIA VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BLOOD SAMPLING; BLUETONGUE INFECTION; BLUETONGUE ORBIVIRUS; CELL STRAIN BHK; CELLULAR IMMUNITY; CONTROLLED STUDY; DNA IMMUNIZATION; ENZYME LINKED IMMUNOSORBENT ASSAY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; TRANSGENIC MOUSE; VERO CELL; VIRUS INFECTION;

ANIMALS; BLUETONGUE; BLUETONGUE VIRUS; CAPSID PROTEINS; CELL LINE; CERCOPITHECUS AETHIOPS; CHICKENS; CRICETINAE; MICE; VACCINATION; VACCINES, DNA; VACCINIA VIRUS; VERO CELLS;

EID: 70649113057     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.10.027     Document Type: Article

References (41)

1. Gibbs E.P., and Greiner E.C. The epidemiology of bluetongue. Comp Immunol Microbiol Infect Dis 17 August-November (3-4) (1994) 207-220
2. Toussaint J.F., Vandenbussche F., Mast J., De Meester L., Goris N., Van Dessel W., et al. Bluetongue in northern Europe. Vet Rec 159 September (10) (2006) 327
3. Mertens P.P., Brown F., and Sangar D.V. Assignment of the genome segments of bluetongue virus type 1 to the proteins which they encode. Virology 135 May (1) (1984) 207-217
4. Roy P., and Noad R. Bluetongue virus assembly and morphogenesis. Curr Top Microbiol Immunol 309 (2006) 87-116
5. Forzan M., Marsh M., and Roy P. Bluetongue virus entry into cells. J Virol 81 May (9) (2007) 4819-4827
6. Hofmann M.A., Renzullo S., Mader M., Chaignat V., Worwa G., and Thuer B. Genetic characterization of toggenburg orbivirus, a new bluetongue virus, from goats, Switzerland. Emerg Infect Dis 14 December (12) (2008) 1855-1861
7. Maan S., Maan N.S., Samuel A.R., Rao S., Attoui H., and Mertens P.P. Analysis and phylogenetic comparisons of full-length VP2 genes of the 24 bluetongue virus serotypes. J Gen Virol 88 February (Pt 2) (2007) 621-630
8. DeMaula C.D., Bonneau K.R., and MacLachlan N.J. Changes in the outer capsid proteins of bluetongue virus serotype ten that abrogate neutralization by monoclonal antibodies. Virus Res 67 March (1) (2000) 59-66
9. Roy P. Bluetongue virus proteins. J Gen Virol 73 December (Pt 12) (1992) 3051-3064
10. Roy P., Boyce M., and Noad R. Prospects for improved bluetongue vaccines. Nat Rev Microbiol 7 February (2) (2009) 120-128
11. Lobato Z.I., Coupar B.E., Gray C.P., Lunt R., and Andrew M.E. Antibody responses and protective immunity to recombinant vaccinia virus-expressed bluetongue virus antigens. Vet Immunol Immunopathol 59 November (3-4) (1997) 293-309
12. Boone J.D., Balasuriya U.B., Karaca K., Audonnet J.C., Yao J., He L., et al. Recombinant canarypox virus vaccine co-expressing genes encoding the VP2 and VP5 outer capsid proteins of bluetongue virus induces high level protection in sheep. Vaccine 25 January (4) (2007) 672-678
13. Wade-Evans A.M., Romero C.H., Mellor P., Takamatsu H., Anderson J., Thevasagayam J., et al. Expression of the major core structural protein (VP7) of bluetongue virus, by a recombinant capripox virus, provides partial protection of sheep against a virulent heterotypic bluetongue virus challenge. Virology 220 June (1) (1996) 227-231
14. Perrin A., Albina E., Breard E., Sailleau C., Prome S., Grillet C., et al. Recombinant capripoxviruses expressing proteins of bluetongue virus: evaluation of immune responses and protection in small ruminants. Vaccine 25 September (37-38) (2007) 6774-6783
15. Jeggo M.H., Wardley R.C., and Taylor W.P. Role of neutralising antibody in passive immunity to bluetongue infection. Res Vet Sci 36 January (1) (1984) 81-86
16. Takamatsu H., and Jeggo M.H. Cultivation of bluetongue virus-specific ovine T cells and their cross-reactivity with different serotype viruses. Immunology 66 February (2) (1989) 258-263
17. Jeggo M.H., and Wardley R.C. Generation of cross-reactive cytotoxic T lymphocytes following immunization of mice with various bluetongue virus types. Immunology 45 April (4) (1982) 629-635
18. Janardhana V., Andrew M.E., Lobato Z.I., and Coupar B.E. The ovine cytotoxic T lymphocyte responses to bluetongue virus. Res Vet Sci 67 December (3) (1999) 213-221
19. Andrew M., Whiteley P., Janardhana V., Lobato Z., Gould A., and Coupar B. Antigen specificity of the ovine cytotoxic T lymphocyte response to bluetongue virus. Vet Immunol Immunopathol 47 August (3-4) (1995) 311-322
20. Stott J.L., and Osburn B.I. Immune response to bluetongue virus infection. Curr Top Microbiol Immunol 162 (1990) 163-178
21. Rodriguez F., and Whitton J.L. Enhancing DNA immunization. Virology 268 March (2) (2000) 233-238
22. Niborski V., Li Y., Brennan F., Lane M., Torche A.M., Remond M., et al. Efficacy of particle-based DNA delivery for vaccination of sheep against FMDV. Vaccine 24 November (49-50) (2006) 7204-7213
23. Lorenzo G., Martin-Folgar R., Rodriguez F., and Brun A. Priming with DNA plasmids encoding the nucleocapsid protein and glycoprotein precursors from Rift Valley fever virus accelerates the immune responses induced by an attenuated vaccine in sheep. Vaccine 26 September (41) (2008) 5255-5262
24. Li S., Rodrigues M., Rodriguez D., Rodriguez J.R., Esteban M., Palese P., et al. Priming with recombinant influenza virus followed by administration of recombinant vaccinia virus induces CD8+ T-cell-mediated protective immunity against malaria. Proc Natl Acad Sci USA 90 June (11) (1993) 5214-5218
25. Aravindaram K., Kuo T.Y., Lan C.W., Yu H.H., Wang P.H., Chen Y.S., et al. Protective immunity against porcine circovirus 2 in mice induced by a gene-based combination vaccination. J Gene Med 11 April (4) (2009) 288-301
26. Amara R.R., Villinger F., Altman J.D., Lydy S.L., O'Neil S.P., Staprans S.I., et al. Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Science 292 April (5514) (2001) 69-74
27. Abaitua F., Rodriguez J.R., Garzon A., Rodriguez D., and Esteban M. Improving recombinant MVA immune responses: potentiation of the immune responses to HIV-1 with MVA and DNA vectors expressing Env and the cytokines IL-12 and IFN-gamma. Virus Res 116 March (1-2) (2006) 11-20
28. Gilbert S.C., Moorthy V.S., Andrews L., Pathan A.A., McConkey S.J., Vuola J.M., et al. Synergistic DNA-MVA prime-boost vaccination regimes for malaria and tuberculosis. Vaccine 24 May (21) (2006) 4554-4561
29. Ramos I., Alonso A., Marcen J.M., Peris A., Castillo J.A., Colmenares M., et al. Heterologous prime-boost vaccination with a non-replicative vaccinia recombinant vector expressing LACK confers protection against canine visceral leishmaniasis with a predominant Th1-specific immune response. Vaccine 26 January (3) (2008) 333-344
30. Fukumoto S., Tamaki Y., Okamura M., Bannai H., Yokoyama N., Suzuki T., et al. Prime-boost immunization with DNA followed by a recombinant vaccinia virus expressing P50 induced protective immunity against Babesia gibsoni infection in dogs. Vaccine 25 January (7) (2007) 1334-1341
31. Calvo-Pinilla E., Rodriguez-Calvo T., Anguita J., Sevilla N., and Ortego J. Establishment of a bluetongue virus infection model in mice that are deficient in the alpha/beta interferon receptor. PLoS ONE 4 4 (2009) e5171
32. Muller U., Steinhoff U., Reis L.F., Hemmi S., Pavlovic J., Zinkernagel R.M., et al. Functional role of type I and type II interferons in antiviral defense. Science 264 June (5167) (1994) 1918-1921
33. Chakrabarti S., Brechling K., and Moss B. Vaccinia virus expression vector: coexpression of beta-galactosidase provides visual screening of recombinant virus plaques. Mol Cell Biol 5 December (12) (1985) 3403-3409
34. Toussaint J.F., Sailleau C., Breard E., Zientara S., and De Clercq K. Bluetongue virus detection by two real-time RT-qPCRs targeting two different genomic segments. J Virol Methods 140 March (1-2) (2007) 115-123
35. Savini G., Maclachlan N.J., Sanchez-Vizcaino J.M., and Zientara S. Vaccines against bluetongue in Europe. Comp Immunol Microbiol Infect Dis 31 March (2-3) (2008) 101-120
36. Roy P., Urakawa T., Van Dijk A.A., and Erasmus B.J. Recombinant virus vaccine for bluetongue disease in sheep. J Virol 64 May (5) (1990) 1998-2003
37. Schwartz-Cornill I., Mertens P.P., Contreras V., Hemati B., Pascale F., Breard E., et al. Bluetongue virus: virology, pathogenesis and immunity. Vet Res 39 September-October (5) (2008) 46
38. Stott J.L., Barber T.L., and Osburn B.I. Immunologic response of sheep to inactivated and virulent bluetongue virus. Am J Vet Res 46 May (5) (1985) 1043-1049
39. Jeggo M.H., Wardley R.C., and Brownlie J. Importance of ovine cytotoxic T cells in protection against bluetongue virus infection. Prog Clin Biol Res 178 (1985) 477-487
40. Jones L.D., Chuma T., Hails R., Williams T., and Roy P. The non-structural proteins of bluetongue virus are a dominant source of cytotoxic T cell peptide determinants. J Gen Virol 77 May (Pt 5) (1996) 997-1003
41. Barros S.C., Cruz B., Luis T.M., Ramos F., Fagulha T., Duarte M., et al. A DIVA system based on the detection of antibodies to non-structural protein 3 (NS3) of bluetongue virus. Vet Microbiol 137 June (3-4) (2009) 252-259